Bailard’s Epizyme, Inc EPZM Stock Holding History

Bailard’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-12,000	Closed	-$163K	–	573
2018 Q2	$163K	Sell	12,000 -13,000	-52%	-$202K	0.01%	504
2018 Q1	$444K	Buy	25,000 +5,000	+25%	+$84.4K	0.03%	344
2017 Q4	$251K	Buy	+20,000	New	+$291K	0.02%	399

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Bailard's EPZM Position: Q3 2018 in Review

Bailard sold out of Epizyme, Inc (EPZM) in Q3 2018, closing a stake of 12,000 shares — an estimated $163K sold.

Bailard first reported a position in EPZM in Q4 2017 and held it in 3 quarters. The position peaked at $444K in Q1 2018. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2018.

Bailard reported no remaining Epizyme, Inc position as of Q3 2018 after selling out during the quarter.
Bailard sold 12,000 Epizyme, Inc shares in Q3 2018, an estimated $163K.
Bailard first reported a position in Epizyme, Inc in Q4 2017 and held it in 3 quarters.
Bailard's Epizyme, Inc position peaked at $444K in Q1 2018.
104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2018.

Based on Bailard's 13F filing for Q3 2018, filed 13 Nov 2018.